Coexistence of TERT promoter and BRAF mutations in cutaneous melanoma is associated with more clinicopathological features of aggressiveness

Virchows Archiv

Volumn 467, Issue 2, 2015, Pages 177-184

  Macerola, Elisabetta ^a   Loggini, Barbara ^b   Giannini, Riccardo ^a   Garavello, Giulia ^b   Giordano, Mirella ^a   Proietti, Agnese ^b   Niccoli, Cristina ^a   Basolo, Fulvio ^a   Fontanini, Gabriella ^a,b  

^a UNIVERSITY OF PISA   (Italy)

^b UNIVERSITY HOSPITAL OF PISA   (Italy)

Author keywords

BRAF mutations; Cutaneous melanoma; Telomerase; TERT promoter mutations

Indexed keywords

B RAF KINASE; GENOMIC DNA; TELOMERASE REVERSE TRANSCRIPTASE; BRAF PROTEIN, HUMAN; TELOMERASE; TERT PROTEIN, HUMAN;

ACRAL LENTIGINOUS MELANOMA; ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER GROWTH; CANCER INFILTRATION; CANCER LOCALIZATION; CANCER REGRESSION; CANCER STAGING; CANCER SURGERY; CLINICAL FEATURE; CONTROLLED STUDY; CUTANEOUS MELANOMA; DNA ISOLATION; FEMALE; GENE MUTATION; GENETIC ASSOCIATION; GENOTYPE; HUMAN; HUMAN TISSUE; INFLAMMATORY INFILTRATE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MITOSIS RATE; MOLECULAR PATHOLOGY; PRIORITY JOURNAL; PROMOTER REGION; RETROSPECTIVE STUDY; SENTINEL LYMPH NODE; START CODON; SUPERFICIAL SPREADING MELANOMA; DISEASE COURSE; GENETICS; MELANOMA; MIDDLE AGED; MOLECULAR GENETICS; MUTATION; NUCLEOTIDE SEQUENCE; PATHOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SKIN TUMOR; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; BASE SEQUENCE; DISEASE PROGRESSION; DNA MUTATIONAL ANALYSIS; FEMALE; GENOTYPE; HUMANS; MALE; MELANOMA; MIDDLE AGED; MOLECULAR SEQUENCE DATA; MUTATION; PROMOTER REGIONS, GENETIC; PROTO-ONCOGENE PROTEINS B-RAF; RETROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SKIN NEOPLASMS; TELOMERASE; YOUNG ADULT;

EID: 84938974506     PISSN: 09456317     EISSN: 14322307     Source Type: Journal    
DOI: 10.1007/s00428-015-1784-x     Document Type: Article

References (39)

1. Jemal A, Saraiya M, Patel P, Cherala SS, Barnholtz-Sloan J, Kim J et al (2011) Recent trends in cutaneous melanoma incidence and death rates in the United States, 1992-2006. J Am Acad Dermatol 65(5 Suppl 1):S17–S25
2. Weinstein D, Leininger J, Hamby C, Safai B (2014) Diagnostic and prognostic biomarkers in melanoma. J Clin Aesthet Dermatol 7(6):13–24
3. Edge SB, Compton CC (2010) The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol 17(6):1471–1474
4. Goppner D, Leverkus M (2011) Prognostic parameters for the primary care of melanoma patients: what is really risky in melanoma? J Skin Cancer 2011:521947
5. Davies MA, Gershenwald JE (2011) Targeted therapy for melanoma: a primer. Surg Oncol Clin N Am 20(1):165–180
6. Swick JM, Maize JC Sr (2012) Molecular biology of melanoma. J Am Acad Dermatol 67(5):1049–1054
7. Hong JW, Lee S, Kim DC, Kim KH, Song KH (2014) Prognostic and clinicopathologic associations of BRAF mutation in primary acral lentiginous melanoma in Korean patients: a preliminary study. Ann Dermatol 26(2):195–202
8. Kumar R, Angelini S, Czene K, Sauroja I, Hahka-Kemppinen M, Pyrhonen S et al (2003) BRAF mutations in metastatic melanoma: a possible association with clinical outcome. Clin Cancer Res 9(9):3362–3368
9. Picard M, Pham Dang N, D’Incan M, Mansard S, Dechelotte P, Pereira B et al (2014) Is BRAF a prognostic factor in stage III skin melanoma? A retrospective study of 72 patients after positive sentinel lymph node dissection. Br J Dermatol 171(1):108–114
10. Rutkowski P, Gos A, Jurkowska M, Switaj T, Dziewirski W, Zdzienicki M et al (2014) Molecular alterations in clinical stage III cutaneous melanoma: correlation with clinicopathological features and patient outcome. Oncol Lett 8(1):47–54
11. Meckbach D, Keim U, Richter S, Leiter U, Eigentler TK, Bauer J et al (2014) BRAF-V600 mutations have no prognostic impact in stage IV melanoma patients treated with monochemotherapy. PLoS One 9(2):e89218
12. Horn S, Figl A, Rachakonda PS, Fischer C, Sucker A, Gast A et al (2013) TERT promoter mutations in familial and sporadic melanoma. Science 339(6122):959–961
13. Huang FW, Hodis E, Xu MJ, Kryukov GV, Chin L, Garraway LA (2013) Highly recurrent TERT promoter mutations in human melanoma. Science 339(6122):957–959
14. Daniel M, Peek GW, Tollefsbol TO (2012) Regulation of the human catalytic subunit of telomerase (hTERT). Gene 498(2):135–146
15. Kim NW, Piatyszek MA, Prowse KR, Harley CB, West MD, Ho PL et al (1994) Specific association of human telomerase activity with immortal cells and cancer. Science 266(5193):2011–2015
16. Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144(5):646–674
17. Heidenreich B, Nagore E, Rachakonda PS, Garcia-Casado Z, Requena C, Traves V et al (2014) Telomerase reverse transcriptase promoter mutations in primary cutaneous melanoma. Nat Commun 5:3401
18. Tallet A, Nault JC, Renier A, Hysi I, Galateau-Salle F, Cazes A et al (2014) Overexpression and promoter mutation of the TERT gene in malignant pleural mesothelioma. Oncogene 33(28):3748–3752
19. Landa I, Ganly I, Chan TA, Mitsutake N, Matsuse M, Ibrahimpasic T et al (2013) Frequent somatic TERT promoter mutations in thyroid cancer: higher prevalence in advanced forms of the disease. J Clin Endocrinol Metab 98(9):E1562–E1566
20. Melo M, da Rocha AG, Vinagre J, Batista R, Peixoto J, Tavares C et al (2014) TERT promoter mutations are a major indicator of poor outcome in differentiated thyroid carcinomas. J Clin Endocrinol Metab 99(5):E754–E765
21. Liu X, Bishop J, Shan Y, Pai S, Liu D, Murugan AK et al (2013) Highly prevalent TERT promoter mutations in aggressive thyroid cancers. Endocr Relat Cancer 20(4):603–610
22. Xing M, Liu R, Liu X, Murugan AK, Zhu G, Zeiger MA et al (2014) BRAF V600E and TERT promoter mutations cooperatively identify the most aggressive papillary thyroid cancer with highest recurrence. J Clin Oncol 32(25):2718–2726
23. Liu X, Wu G, Shan Y, Hartmann C, von Deimling A, Xing M (2013) Highly prevalent TERT promoter mutations in bladder cancer and glioblastoma. Cell Cycle 12(10):1637–1638
24. Griewank KG, Murali R, Schilling B, Schimming T, Moller I, Moll I et al (2013) TERT promoter mutations are frequent in cutaneous basal cell carcinoma and squamous cell carcinoma. PLoS One 8(11):e80354
25. Killela PJ, Reitman ZJ, Jiao Y, Bettegowda C, Agrawal N, Diaz LA Jr et al (2013) TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal. Proc Natl Acad Sci U S A 110(15):6021–6026
26. Populo H, Boaventura P, Vinagre J, Batista R, Mendes A, Caldas R et al (2014) TERT promoter mutations in skin cancer: the effects of sun exposure and X-irradiation. J Invest Dermatol 134(8):2251–2257
27. Griewank KG, Murali R, Puig-Butille JA, Schilling B, Livingstone E, Potrony M, et al (2014) TERT promoter mutation status as an independent prognostic factor in cutaneous melanoma. J Natl Cancer Inst 106 (9)
28. LeBoit PE, Burg G, Weedon D, Sarasin A (eds) (2006) WHO classification of tumours—pathology and genetics of skin tumours. IARC Press, Lyon
29. Lupi C, Giannini R, Ugolini C, Proietti A, Berti P, Minuto M et al (2007) Association of BRAF V600E mutation with poor clinicopathological outcomes in 500 consecutive cases of papillary thyroid carcinoma. J Clin Endocrinol Metab 92(11):4085–4090
30. Vinagre J, Pinto V, Celestino R, Reis M, Populo H, Boaventura P et al (2014) Telomerase promoter mutations in cancer: an emerging molecular biomarker? Virchows Arch 465(2):119–133
31. Vinagre J, Almeida A, Populo H, Batista R, Lyra J, Pinto V et al (2013) Frequency of TERT promoter mutations in human cancers. Nat Commun 4:2185
32. Eklof V, Wikberg ML, Edin S, Dahlin AM, Jonsson BA, Oberg A et al (2013) The prognostic role of KRAS, BRAF, PIK3CA and PTEN in colorectal cancer. Br J Cancer 108(10):2153–2163
33. Basolo F, Torregrossa L, Giannini R, Miccoli M, Lupi C, Sensi E et al (2010) Correlation between the BRAF V600E mutation and tumor invasiveness in papillary thyroid carcinomas smaller than 20 millimeters: analysis of 1060 cases. J Clin Endocrinol Metab 95(9):4197–4205
34. Liau JY, Tsai JH, Jeng YM, Chu CY, Kuo KT, Liang CW (2014) TERT promoter mutation is uncommon in acral lentiginous melanoma. J Cutan Pathol 41(6):504–508
35. Houben R, Vetter-Kauczok CS, Ortmann S, Rapp UR, Broecker EB, Becker JC (2008) Phospho-ERK staining is a poor indicator of the mutational status of BRAF and NRAS in human melanoma. J Invest Dermatol 128(8):2003–2012
36. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S et al (2002) Mutations of the BRAF gene in human cancer. Nature 417(6892):949–954
37. Wan PT, Garnett MJ, Roe SM, Lee S, Niculescu-Duvaz D, Good VM et al (2004) Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 116(6):855–867
38. Rao VN, Reddy ES (1994) elk-1 proteins interact with MAP kinases. Oncogene 9(7):1855–1860
39. Whitmarsh AJ, Shore P, Sharrocks AD, Davis RJ (1995) Integration of MAP kinase signal transduction pathways at the serum response element. Science 269(5222):403–407